Targeting ERβ with a novel agonist in the treatment of peripheral neuropathies and metabolic disease
TS-075181 — PROBLEM
Metabolic diseases and peripheral neuropathies represent a major public health burden in the United States, and the risks increase as we age. Metabolic diseases, including diabetes and obesity, and peripheral neuropathy (PN) affect approximately 25-45% and 10-20% of U.S. adults aged 50-70 r…
- College: College of Medicine (COM)
- Inventors: Townsend, Kristy
- Licensing Officer: Willson, Christopher
